IMC Logo.jpg
Immuron Business Update: Letter to Shareholders
June 22, 2023 06:00 ET | Immuron Limited
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...
IMC Logo.jpg
Immuron Initiates Recruitment of Travelan® Clinical Study
May 30, 2023 06:00 ET | Immuron Limited
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...
IMC Logo.jpg
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
January 18, 2023 05:00 ET | Immuron Limited
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in...
IMC Logo.jpg
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
October 04, 2022 06:00 ET | Immuron Limited
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...
IMC Logo.jpg
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
May 13, 2021 06:00 ET | Immuron Limited
Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief...
IMC Logo.jpg
Immuron Travelers’ Diarrhea Market Update
October 12, 2020 06:00 ET | Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
IMC Logo.jpg
Immuron sales surge by 66% in the Third Quarter of FY19
April 15, 2019 09:00 ET | Immuron Limited
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...